CSF markers for incipient Alzheimer's disease

Area of Science:

• Neurology
• Biochemistry
• Geriatrics

Background:

• Early diagnosis of Alzheimer's disease (AD) is essential for initiating timely symptomatic treatments.
• Current methods cannot reliably distinguish between mild cognitive impairment (MCI) that progresses to AD dementia and benign MCI.
• Developing accurate biomarkers for incipient AD in MCI patients is a significant clinical need.

Purpose of the Study:

• To evaluate the diagnostic potential of cerebrospinal fluid (CSF) biomarkers for identifying early Alzheimer's disease in patients with mild cognitive impairment.
• To assess whether specific CSF biomarkers can accurately predict the progression of MCI to AD dementia.

Main Methods:

• Analysis of cerebrospinal fluid (CSF) biomarkers, including total tau protein, phosphorylated tau protein, and the 42 amino-acid residue form of amyloid-beta.
• Correlation of biomarker levels with clinical diagnosis and progression of mild cognitive impairment (MCI) to Alzheimer's disease (AD) dementia.

Main Results:

• CSF biomarkers, specifically total tau, phosphorylated tau, and amyloid-beta 42, show potential for high diagnostic accuracy.
• These biomarkers, when interpreted within the appropriate clinical context, may help identify patients with MCI who are likely to develop AD dementia.

Conclusions:

• Cerebrospinal fluid biomarkers hold promise for the early and accurate diagnosis of Alzheimer's disease in patients with mild cognitive impairment.
• The judicious use of tau and amyloid-beta biomarkers in a clinical setting could significantly improve the identification of incipient AD, enabling earlier intervention.